We are a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor, ME-344, a novel mitochondrial inhibitor, and PWT143, a highly selective PI3K delta inhibitor.
[ Read more ]
MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies
[ May 4, 2015 ] [ Poster ] [ Abstract ]
[ Am J Cancer Res ] [ Cancer ]
MEI Pharma Announces Top-Line Data from Phase II Clinical Study of Pracinostat in Front-Line MDS
[ March 23, 2015 ]
Click here for our 2014 Annual Review